Miguel Perales, MD
CAR T-cell therapy has emerged as a promising therapy for select patients with non-Hodgkin lymphoma (NHL), but as research continues and the treatment is used in a real-world setting, overarching guidelines must be set in place, explained Miguel-Angel Perales, MD.
“The results of CAR T cells in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma are very promising,” said Perales. “We'll have to see what the role of CAR T cells is for these diseases, but it's definitely a therapy that's very effective.”
... to read the full story